[
    [
        {
            "time": "2021-12-31",
            "original_text": "2021收官日！NMPA再批3款1类新药，恒瑞下了“双黄蛋”！",
            "features": {
                "keywords": [
                    "NMPA",
                    "1类新药",
                    "恒瑞医药",
                    "双黄蛋"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2021收官日！NMPA再批3款1类新药，恒瑞下了“双黄蛋”！",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "年终盘点|2021年十大\"争议\"白马股",
            "features": {
                "keywords": [
                    "年终盘点",
                    "争议",
                    "白马股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "年终盘点|2021年十大\"争议\"白马股",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "国家药监局批准恒瑞医药脯氨酸恒格列净片上市",
            "features": {
                "keywords": [
                    "国家药监局",
                    "恒瑞医药",
                    "脯氨酸恒格列净片"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国家药监局批准恒瑞医药脯氨酸恒格列净片上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药脯氨酸恒格列净片、羟乙基磺酸达尔西利片获批上市",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "脯氨酸恒格列净片",
                    "羟乙基磺酸达尔西利片"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药脯氨酸恒格列净片、羟乙基磺酸达尔西利片获批上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "2021年A股年终盘点：十大“水逆”板块在哪里？",
            "features": {
                "keywords": [
                    "A股",
                    "年终盘点",
                    "水逆",
                    "板块"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "2021年A股年终盘点：十大“水逆”板块在哪里？",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "21硬核研报丨2022医药行业投资前瞻：创新药出海潮来临 “卖水人”CXO高景气值得期待",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资前瞻",
                    "创新药",
                    "CXO",
                    "高景气"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "21硬核研报丨2022医药行业投资前瞻：创新药出海潮来临 “卖水人”CXO高景气值得期待",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药：公司目前已上市创新药注射用卡瑞利珠单抗、硫培非格司亭均属于生物制药",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "创新药",
                    "卡瑞利珠单抗",
                    "硫培非格司亭",
                    "生物制药"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：公司目前已上市创新药注射用卡瑞利珠单抗、硫培非格司亭均属于生物制药",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "恒瑞医药：PD-1联合阿帕替尼治疗晚期肝癌的海外三期临床试验目前进展顺利",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PD-1",
                    "阿帕替尼",
                    "肝癌",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：PD-1联合阿帕替尼治疗晚期肝癌的海外三期临床试验目前进展顺利",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "400余家药企研发人员已超16.7万，研发速度不断提升",
            "features": {
                "keywords": [
                    "药企",
                    "研发人员",
                    "研发速度"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "400余家药企研发人员已超16.7万，研发速度不断提升",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-30",
            "original_text": "A股融资融券日报：两融余额增加32.82亿元（12月30日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加32.82亿元（12月30日）",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "中国医药产业迎来“创新药”时代 401家公司研发人员超16.7万",
            "features": {
                "keywords": [
                    "医药产业",
                    "创新药",
                    "研发人员"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中国医药产业迎来“创新药”时代 401家公司研发人员超16.7万",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-12-31",
            "original_text": "医改进入“深水区” 新政频出药企如何应对行业大变局？",
            "features": {
                "keywords": [
                    "医改",
                    "新政",
                    "药企",
                    "行业变局"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医改进入“深水区” 新政频出药企如何应对行业大变局？",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]